Nasipral (Ipratropium Bromide)

Ipratropium bromide is a competitive antagonist of muscarinic acetylcholine receptors located on the nasal mucosa. By blocking these receptors, it inhibits the action of acetylcholine, leading to reduced glandular secretion and vasodilation, which diminishes nasal mucus production and swelling, thereby easing congestion.

The prescribed dose of Nasipral is determined by the treating healthcare professional based on the patient’s age, severity of symptoms, and clinical response. Typically, one or two sprays per nostril may be recommended, but exact dosing instructions must be obtained from a qualified prescriber.

Safety data for ipratropium bromide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a healthcare provider after evaluating the individual circumstances.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity of Nasipral. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any temperature control) and necessary import documentation.

Unlike topical decongestants such as oxymetazoline that cause vasoconstriction, Nasipral’s ipratropium bromide reduces nasal secretions through anticholinergic action, resulting in a lower risk of rebound congestion (rhinitis medicamentosa). It is generally considered suitable for longer‑term use under medical supervision, whereas sympathomimetic decongestants are recommended for short‑term relief only.

Nasipral should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and direct sunlight. Keep the bottle tightly closed when not in use and out of reach of children. Do not freeze or expose to extreme temperatures.

Nasipral is administered as a nasal spray. The user should gently blow the nose, tilt the head slightly forward, insert the nozzle into one nostril, and press the actuator to deliver the prescribed number of sprays. The same procedure is repeated for the other nostril if required. Avoid inhaling deeply during administration to limit systemic absorption.

Although generally well tolerated, serious adverse reactions can occur, including allergic responses such as rash, swelling of the face or throat, and anaphylaxis. Rarely, patients may experience bronchospasm, severe nasal bleeding, or paradoxical worsening of congestion. Any of these symptoms require immediate medical attention.

Nasipral should not be used by individuals with known hypersensitivity to ipratropium bromide, atropine, or any other components of the formulation. Caution is also advised for patients with narrow‑angle glaucoma, urinary retention, or severe gastrointestinal disorders, and it should be avoided in children unless specifically prescribed by a qualified clinician.